INTRODUCTION: Dintwtic retinopathy is the leading cause of blindness
in patients aged 20-74 years in the United States, Chew and Ferris
(2001). Diabetic macular edema (DME) is a manifestation of diabetic rednopathy
that produces loss of central vision. Klein, et aL, (1984). Two different
subtypes of DME are recognized. Focal macuirir edema, and diffuse
macular edema, Ciardella, et aL, (2004). intrauitreal injection has
been proposed as a new technique in the treatment, Jonas, et al., (2003).
Triamcinolone Acetonide (TA) is a synthetic glucocorticoid analog with
marked anti-inflammatory action, used to take the advantage of its antiedematous
effect, Jonas and SOfker (2001). Anti-vascular endothelial
growth factor (VEGF) therapy has probably been one of the most promising
breakthroughs in medical retina treatment Brwon, et aL, (2006). Bevacizumab,
a full length monoclonal antibody binding all isoforms of
VEGF, Michels, et al., (2005) and Moshfeght et al., (2006) . Bevacizurnab
is rapidly becoming one of the leading treatments for neovascular diseases,
Fung, et aL, (2006) and Jorge, et aL, (2006) . |
